Background: 4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA), a nucleoside reverse transcriptase inhibitor (NRTI), exerts potent activity against a wide spectrum of HIV-1 variants, including multi-drug-resistant HIV-1 isolates. EFdA is currently under clinical trials in the US as a peroral QD-possible therapeutic against HIV-1 infection and AIDS. We have recently selected in vitro HIV-1 variants resistant against EFdA (HIV-1EFdA-R), carrying M41L/D67D/T69G/K70R/L74I/V75T/M184V/T215F/K219Q substitutions in reverse transcriptase (Maeda K et al. Antiviral Therapy 19:179-189, 2014). In the present study, we newly designed and synthesized a variety of novel 4′-modified NRTIs, which exert activity against various multi-drug-resistant-HIV-1 variants including HIV-1EFdA-R.
Methods: Anti-HIV-1 activity of EFdA and various newly synthesized EFdA-related NRTIs were examined using various cell-based assays including the MTT assay and p24 assay. Cytotoxicity of such NRTIs was also determined.
Results: Multiple EFdA-related NRTIs were identified to be active against wild-type HIV-1 (HIV-1WT) with IC50 values of 2 – 207 nM, most of which were also active against viruses carrying conventional multi-NRTI-resistance-associated amino acid substitutions such as K65R, K70R, and M184V (HIV-1MDRs) with IC50 values of 3 – 404 nM. However, most of such 4′-modified NRTIs failed to be active against HIV-1EFdA-R (>1,000 nM): only two 4′-modified-pyrimidine-based NRTIs, YMS-99066 and YMS-03072, were identified to be active against HIV-1EFdA-R with IC50 values of 91 and 131 nM, respectively. Against HIV-1WT and HIV-1MDRs, EFdA exerted the most potent activity with IC50 values of 0.1 – 2 nM. Against HIV-1EFdA-R, EFdA also exerted the most potent activity with IC50 value of 44 nM. The CC50 value of EFdA was 19.2 µM with a selectivity index of 64,000.
Conclusions: We newly synthesized various 4′-modified NRTIs and tested their activity against HIV-1WT, HIV-1MDRs, and HIV-1EFdA-R. The present data demonstrate that among a variety of 4′-modified purine- and pyrimidine-based NRTIs, EFdA persistently exerts the most potent activity against even EFdA-selected HIV-1EFdA-R and warrant further clinical development as a novel QD-possible NRTI with an extremely high genetic barrier and potency against a variety of multi-drug-resistant HIV-1 variants.